CAS NO: | 947687-13-0 |
包装: | 50mg, 100mg, 250mg |
规格: | ≥98% |
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. References: Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.
纯度:≥98%
CAS:947687-13-0